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Abstract
Background: This study sought to evaluate the effect of sow vaccination against Porcine circovirus 2 (PCV2) on
reproductive parameters during two consecutive reproductive cycles. The study was performed in a PCV2
subclinical infected breeding herd (PCV2 circulation but absence of major reproductive problems). Ninety-four
pregnant sows were primo-immunized with a commercial PCV2 vaccine and ninety-seven were injected with
phosphate-buffered saline at 6 and 3 weeks before the first studied farrowing, and then boosted at 2 weeks
before the second one. Blood samples were taken throughout the study to assess PCV2 DNA load and antibodies.
At farrowing, main reproductive parameters and piglet vitality index were registered. In addition, in those litters with
more than three mummified or stillborn piglets, microscopic examination and PCV2 antigen detection in foetal
myocardium was done.
Results: Vaccinated sows showed significantly higher antibody levels compared to the non-vaccinated counterparts.
PCV2 DNA was only detected at farrowing in 2 (4.2%) non-vaccinated sows. Vaccinated sows had 1.3 more live-born
piglets per litter at the second cycle than non-vaccinated counterparts. Piglets from vaccinated sows had significantly
higher (+ 12.7%) vitality score than the ones born from non-vaccinated sows. No PCV2 compatible lesions neither PCV2
antigen were detected in the tested foetal hearts.
Conclusions: The present study represents a first attempt to demonstrate that PCV2 sow vaccination may have a
positive influence on prolificacy and vitality of the offspring in a subclinical infected breeding herd. However, since
reproductive outcomes at farm level may be affected by a number of factors, further studies would be needed to
confirm this association.
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Background
Porcine circovirus 2 (PCV2) is a small and ubiquitous
single-stranded DNA virus with a great economic im-
portance for the swine industry [1]. This virus is linked
to a number of diseases collectively named Porcine cir-
covirus diseases (PCVD) [2]. Among these, PCV2 has
been shown to be involved in reproductive disorders in
sows such as return-to-oestrus, late term abortions and
increased number of mummified, stillborn and non-
viable piglets at birth [3–8], as well as early embryo mor-
tality [7, 9]. In this context, PCV2 can be transmitted to
the embryos as soon as they get rid of the zona pellucida
[10], to the foetus through the placenta [11] and to the
new-born piglets by colostrum [12]. Under experimental
conditions, some studies have demonstrated that infec-
tion of sows by both artificial insemination (AI) with
PCV2-spiked semen or PCV2 inoculation can cause
foetal infection and reproductive disorders [5, 13]. More-
over, foetal infections and reproductive abnormalities
have been reproduced by intrauterine inoculation of foe-
tuses or foetal liquids [14–16]. However, at farm level, it
is feasible that a proportion of PCV2 effects on
reproduction are linked to embryonic death [7, 10],
which nowadays is still beyond the diagnostic capacity.
This overall situation leads to the fact that clinical and
noticeable reproductive disease (PCV2-RD) attributed to
PCV2, at field level, is infrequent [6, 11, 17].
PCV2 vaccination in sows prior to farrowing is fo-
cused on the protection of the offspring by antibody
transfer through the colostrum. This strategy has re-
sulted in prevention of PCV2-systemic disease (PCV2-
SD) [18], decrease of viremia [19–21] and PCV2 tissue
load [22] in their progeny, and improvement of the aver-
age daily weight gain (ADWG) in subclinically infected
finisher pigs [23]. Despite these facts, it has been dem-
onstrated that sow vaccination does not fully prevent
PCV2 vertical transmission [24–27].
In contrast, influence of PCV2 sow vaccination on
reproductive parameters has been poorly investigated.
As for example, this type of problems has been tackled
as a secondary goal and in a very limited number of
sows (1-3 sows per group) in some experimental studies
[24, 25, 27]. At farm level, this issue has only been
assessed in two peer-reviewed studies: firstly in one farm
suffering from PCV2-SD in growing pigs but without evi-
dent reproductive problems (PCV2-SI scenario in the
sow herd) [23] and, secondly, in one farm with PCV2-
SD among weaners and serious reproductive problems
in sows [28]. Whereas in the first study no significant
differences on the main reproductive parameters be-
tween treatments were detected, in the second one an
improvement of all measured reproductive parameters
were recorded. However, information about the effect
of this vaccination strategy on reproductive parameters
in a farm with neither reproductive nor PCV2-SD prob-
lems (scenario resembling a situation of most breeding
herds) is missing in the peer-reviewed literature. Thus,
the current work was aimed to evaluate the potential
effects of sow vaccination against PCV2 on serological
(ELISA), virological (quantitative PCR (qPCR)) and repro-
ductive parameters during two consecutive reproductive
cycles in a PCV2 subclinical infection (PCV2-SI) scenario




The study was conducted in a 1900-sow farm located in
Catalonia (Spain). This farm worked with weekly farrow-
ing batches in all-in/all-out management system. The
vaccination program applied by routine included sow
immunization against Porcine reproductive and respira-
tory syndrome virus (PRRSV), Aujeszky’s disease virus,
Swine influenza virus, Porcine parvovirus, Erysipelothrix
rhusiopathiae, Escherichia coli and Clostridium perfrin-
gens. Piglets were vaccinated against Mycoplasma hyop-
neumoniae and PCV2 at 5 days pre-weaning and at
weaning, respectively. Weaning was performed at 3 weeks
of age. Moreover, no signs of any major pig diseases were
present and herd immunity status against PRRSV was
deemed as “positive-stable” (II-A) [29].
This farm had average reproductive parameter per-
formance in line with the average Spanish national re-
cords (www.bdporc.irta.es) and did not suffer from
PCVD clinical signs. Prior to the start of the study,
PCV2 antibody detection was confirmed (Ingezim Circo
IgG 11.PCV.K1®, Ingenasa, Madrid, Spain) in 7 out of 7
(100%) gilts and in 33 out of 38 (87%) sows of different
parity that have never been vaccinated before against
PCV2 (Fig. 1). In addition, antibody levels were hetero-
geneous (ranging from 0.20 to 1.49 ELISA S/P values),
with a decreasing value trend in older sows.
Study design
One hundred and ninety-one healthy sows were selected
in three consecutive farrowing batches at 6 weeks pre-
farrowing. These animals were individually ear-tagged
and distributed in two treatment groups (Table 1).
Randomization was performed according to parity (from
1 to 8) and the number of total-born and live-born pig-
lets at the former farrowing. The comparability of the
obtained groups was also checked for number of piglets
weaned in the previous farrowing. Sample size was cal-
culated using the expected differences between treat-
ment groups in terms of magnitude of the parameters
used for randomization. For this purpose, a statistical
and qualitative data analysis software (GPower, University
of Düsseldorf) was used. The study was conducted in two
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consecutive reproductive cycles. Sows were vaccinated
by intramuscular injection with 2 mL of a commercial
inactivated PCV2 vaccine (CIRCOVAC®, Batch number:
L414725) at time points indicated in Table 1. Non-
vaccinated sows received 2 ml of phosphate buffer sa-
line (PBS) at the same time points and by the same
route. Animals with different treatments were located
comingled in the same gestation pens as well as in the
same farrowing unit rooms.
Study design is represented in Table 2. Any abnormality
related to general state, condition of the skin, hair and
mucosa, respiratory, digestive and nervous signs, and
locomotive problems was registered at different time
points. At the end of the first experimental reproductive
cycle, as part of routine breeder management, sows with
major pathologies (lameness, injuries, etc.) and high parity
(older sows) were excluded from the study. In addition,
those sows showing return-to-oestrus (non-pregnant
ones) in regards their counterparts, were registered and
removed from the second cycle. Furthermore, sow mor-
tality was also recorded.
Blood samples from a randomly selected subpopula-
tion of sows (n = 48 per treatment group) were taken at
different time points throughout the first (at vaccination,
farrowing and weaning) and second (at farrowing) gesta-
tional cycle (Table 2). Once in the laboratory, these sam-
ples were allowed clotting, and were centrifuged at
3200 rpm during 20 min at 4 °C. All sera were aliquoted
and stored at − 20 °C until testing.
In each reproductive cycle, the following reproductive
parameters were registered: return-to-oestrus, abortion
rate, interval between expected and real farrowing date,
weaning-to-fertile mating interval and number of live-
born, mummified, stillborn, crushed and weaned piglets
per litter.
All piglets issued from the studied sows (first and
second gestational cycle) were ear-tagged, gender re-
corded and assigned a vitality index (VI) (see section
Vitality index scoring method). Cross-fostering was
only allowed within sows of the same treatment group
and, when possible, within the same parity group (1st
parity; 2nd-4th parity; 5th-8th parity). Moreover, from
those litters with more than three mummified or
stillborn foetuses, heart samples were taken and fixed
in 10% neutral-buffered formalin for further histo-
pathological analysis and PCV2 antigen detection by
Table 1 Treatment distribution of sows and vaccination schedule in both gestational cycles
Population Nb Group Treatment Volume and doses Number of
sows bledFirst gestational cycle Second gestational cycle
Sows 94 (75) V PCV2 vaccinea 2 ml at 6 and 3 weeks
pre-farrowing
2 ml at 2 weeks
pre-farrowing
48
97 (75) NV PBS 48
V vaccinated, NV non-vaccinated
aAnimals were vaccinated with CIRCOVAC®
bIn parentheses, number of sows remaining for the second gestational cycle in each group
Fig. 1 Individual PCV2 ELISA S/P results in serum samples from gilts and sows with different parity number prior to the start of the study
(farm screening)
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immunohistochemistry (IHC) (see section Histopathology
and IHC in heart of foetuses). All piglets included in the
study were monitored for clinical signs and mortality
during lactation.
Housing conditions, feeding system, feed characteris-
tics and health management remained consistent along
the course of the trial, and were the same for both ex-
perimental groups. The present study was approved by
the Ethics Committee for Animal Experimentation from
the Universitat Autònoma de Barcelona and the Animal
Experimentation Commission from the local govern-
ment (Dpt. de Medi Ambient i Habitatge from the
Generalitat de Catalunya; Reference 5796).
Vitality index scoring method
The vitality of the piglets (within the first 3 h of life,
approximately) was assessed according to a previously
published index [30]. The behavioral variables evaluated
were the following:
 Udder stimulation (U): 0 = no head movements, no
emulating udder stimulation movements or no
searching behavior within 30 s; 1 = head movements,
emulating udder stimulation movements or
searching behavior within 30 s.
 Number of completed circles around the enclosure
(NCC): 0 = Not able to turn piglet body axis 360°
from its initial orientation nor able to walk along the
limits of the bucket; 1 = Able to turn piglet body axis
360° from its initial orientation or walk along the
limits of the bucket once within 30 s; 2 = Able to
turn piglet body axis 360° from its initial orientation
or walk along the limits of the bucket at least twice
within 30 s.
Histopathology and IHC in heart of foetuses
After fixation by immersion in 10% neutral-buffered for-
malin and embedding in paraffin, tissue sections were
processed routinely for haematoxylin/eosin (HE) staining.
These samples were examined under a light microscope
for the evaluation of potential microscopic lesions.
For IHC technique, serial sections (3 μm) were
dewaxed in xylene and rehydrated through graded alco-
hols. Endogenous peroxidase was blocked with 3% of
H2O2 (30%) in methanol during 30 min, followed by a
5-min wash in distilled water. Sections were then sub-
jected to proteolytic enzyme digestion with protease
type XIV (Sigma, Madrid, Spain) at a concentration of
0.1% in PBS for 8 min at 37 °C. After digestion, the sec-
tions were washed three times during 5 min in PBS.
Then, these sections were incubated for 1 h at room
temperature with 2% of bovine serum albumin (Sigma,
Madrid, Spain) in PBS. A specific monoclonal antibody
(isotype IgG2a) (Ingenasa, Madrid, Spain) against PCV2
Cap protein was applied at a 1 in 1000 dilution in 2% of
bovine serum albumin in PBS (pH 7.4) to tissue sec-
tions and incubated overnight at 4 °C. Sections were
then washed three times in PBS for 5 min. After washing,
sections were incubated for 45 min with peroxidase-
labelled polymer-horseradish peroxidase conjugated to
goat anti-mouse immunoglobulins (Envision 1 System-
HRP-DAB; Dako, Barcelona, Spain). Staining was
completed by incubation with 3,3′diaminobenzidine
chromogen solution (Envision 1 System-HRP-DAB;
Dako, Barcelona, Spain). Sections were counterstained
with Mayer’s haematoxylin, dehydrated, and mounted.
Samples were examined under a light microscope for
the analysis of immunostaining.
DNA extraction and real-time quantitative PCR
DNA was extracted from 200 μl of serum by using the
MagMAX™ Pathogen RNA/DNA Kit (Applied Biosys-
tems) following the manufacturer’s instructions. DNA
obtained was suspended in 90 μl of elution solution. To
quantify PCV2 DNA in serum samples, a real-time
qPCR assay (LSI VetMAX™ Porcine Circovirus Type 2-
Quantification, Life Technologies) was performed. Each
extraction and qPCR plate included negative controls
where DNA was substituted for diethylpyrocarbonate
Table 2 Study design schedule
Population First gestational cycle Second gestational cycle
6 weeks pre-farrowing 3 weeks pre-farrowing Farrowing Weaning AI 2 weeks pre-farrowing Farrowing Weaning
Sows CS CS CS CS CS CS CS
T T T
BL BL BL BL
RP RP
Piglets S CS S CS
CS CS
VI VI
AI artificial insemination, CS clinical signs, T treatment application, BL blood sampling, RP reproductive parameters assessment, S sex recording, VI vitality index
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(DEPC)-treated water. In addition, each sample reaction
had an internal positive control (IPC) to monitor DNA ex-
traction and amplification procedures. Viral concentrations
were expressed as the mean log10 PCV2 genome copies/
mL ± standard deviation (SD).
Indirect ELISA for detecting anti-PCV2 IgG antibodies
All serum samples were tested by Ingezim Circo IgG 11.
PCV.K1® assay (Ingenasa, Madrid, Spain). Optical dens-
ity (OD) was measured at 450 nm by PowerWave XS
reader (BioTek). Mean positive cut-off was established at
0.3 OD (± SD) following kit’s instructions (positive cut-
off = OD of negative control + 0.25). ELISA results were
expressed as mean S/P ratio (OD of sample/OD of posi-
tive control for each ELISA plate) ± SD.
Statistical analyses
Statistical analyses were carried out using SAS v9.4, SAS
Institute Inc., Cary, NC, USA. Significance level was set
at p < 0.05. Proportion of animal mortality and exclusion
rates between vaccinated and non-vaccinated sows was
compared using Fisher exact test and Chi-square test,
respectively. Reproductive parameters from all sows in-
cluded in the study were analyzed and compared be-
tween experimental groups within each reproductive
cycle (intra-cycle comparison) using the non-parametric
Wilcoxon test. In addition, reproductive parameters
from those sows farrowing in both reproductive cycles
were compared between cycles (inter-cycle comparison)
using generalized linear mixed models. Treatment, cycle
and their interaction were considered as a fixed effects
and sow as a random effect. Percentage of positive qPCR
serum samples and mean log10 PCV2 copies/mL among
those qPCR positive samples were compared at each
sampling point using Fisher exact tests and Wilcoxon
tests, respectively. ELISA S/P values were analyzed using
a linear mixed model. For the analysis of VI (U and
NCC), clinical signs in piglets and piglet mortality dur-
ing lactation generalized linear mixed models were used.
Treatment was considered as a fixed effect and sow as a
random effect.
Results
Clinical signs in sows
No evident clinical signs were observed in any of the
sows, but one, throughout the study. The particular af-
fected sow was from the vaccinated group and devel-
oped severe lameness at the end of the first reproductive
cycle, when it was excluded from the study.
Mortality and exclusion in sows
Mortality and exclusion rates and reason of exclusion
are detailed in Table 3. In both reproductive cycles, non-
vaccinated sows showed numerically higher (but not sig-
nificant) mortality than the vaccinated ones. Moreover,
no statistically significant differences among treatment
groups were observed between the two reproductive cy-
cles with regards to the number of excluded females and
the exclusion reason.
Reproductive parameters
Comparison between experimental groups within each
reproductive cycle (intra-cycle comparison)
Main reproductive parameters for each treatment group
at first and second reproductive cycles are listed in
Table 4. Number of live-born piglets at the second cycle
was significantly (p < 0.05) higher (+ 1.3 piglets/sow) in
the vaccinated group. In addition, a tendency of higher
number of weaned piglets (+ 0.8) in vaccinated sows was
observed (p < 0.1). Moreover, most reproductive parame-
ters (return-to-oestrus [− 0.6%], interval between ex-
pected and real farrowing date [− 0.3 days] and number
of mummified [− 0.1] piglets per litter) were numerically
better for the vaccinated group in the second cycle.
Whereas at first reproductive cycle number of stillborn
piglets per litter was significantly higher in the vacci-
nated group, at the second period this parameter was
numerically higher in the non-vaccinated one. Besides,
number of crushed piglets at birth was numerically
higher in the vaccinated group at first and second cycles.
Regarding the abortions, there was only one abortion in
each cycle for each treatment group. In addition, piglets
from vaccinated sows had significantly higher vitality
Table 3 Number and percentage (in brackets) of dead and excluded sows and reason of exclusion
Treatment V (n = 94) NV (n = 97)
Mortality in first reproductive cycle 2 (2.13%) 5 (5.15%)
Exclusion at the end of the first reproductive cycle Return to oestrus 13 (13.83%) 14 (14.43%)
Culling. Old sow 2 (2.13%) 1 (1.03%)
Culling. Lameness 1 (1.06%) 0 (0%)
Human mistakes (vaccination, misplaced sows…) 1 (1.06%) 2 (2.06%)
TOTAL excluded animals 17 (18.09%) 17 (17.53%)
Mortality in second reproductive cycle 0 (0%) 2 (2.67%)
No statistically significant differences (p < 0.05) among experimental groups were observed
V vaccinated, NV non-vaccinated
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than the ones derived from non-vaccinated sows in both
reproductive cycles. Specifically, piglets from vaccinated
group showed higher percentage of head movements
emulating the udder searching (statistically significant at
first cycle) and greater mobility (statistically significant
in both cycles) during the 30 tested seconds than the
ones from non-vaccinated group.
Comparison of each experimental group between
reproductive cycles (inter-cycle comparison)
In the second cycle, vaccinated sows had significantly
different number of live-born (+ 1.17), crushed (+ 0.34)
and stillborn (− 0.55) piglets per litter in comparison to
the same sows (n = 75) in the first reproductive cycle.
Moreover, non-vaccinated sows (n = 75) showed at
their second cycle significantly higher number of
crushed (+ 0.32) and stillborn (+ 0.36) piglets per litter
than in their previous cycle. No statistically significant
differences between cycles were observed for the rest
of the parameters.
Clinical signs and mortality in suckling piglets
In the first cycle, although the number of sows included
in the study was 94 and 97 for the vaccinated and non-
vaccinated groups, respectively, the number of litters
monitored during the first lactation period was 93 and
96, since there was one premature farrowing and one
abortion in the vaccinated and non-vaccinated groups,
respectively. In this context, 9 out of 93 (9.7%) and 10
out of 96 (10.4%) litters from vaccinated and non-
vaccinated sows, respectively, evidenced diarrhoea. Be-
sides, 65 out of 1333 (4.9%) and 53 out of 1307 (4.1%)
piglets from vaccinated and non-vaccinated sows,
respectively, showed neurological signs clinically at-
tributed to Streptoccocus suis (S. suis) infection. In the
second suckling period, 8 out of 74 (10.8%) and 9 out
of 75 (12%) litters from vaccinated and non-vaccinated
sows, respectively, suffered from diarrhoea. In addition,
prevalence of S.suis-like infections was reduced, recording
only 3 out of 1141 (0.3%) and 2 out of 1062 (0.2%) clinical
cases in piglets from vaccinated and non-vaccinated sows,
respectively. No statistically significant differences
between treatments in terms of diarrhoea and neuro-
logical signs were observed for any of the two lacta-
tion periods.
Piglet mortality rate (including crushed piglets around
birth) in lactation was 13.9% and 16.8% for piglets from
vaccinated sows at first and second cycles, respectively.
Similarly, pre-weaning mortality rate in piglets from
non-vaccinated sows was 11.4% and 15.2% at first and
second suckling periods, respectively. However, no sta-
tistically significant differences among treatment groups
were observed in any of the two lactation periods.
Microscopic evaluation and PCV2 antigen detection in
foetal heart tissues
Although, 14 litters (7.33%) from the first farrowing
cycle had more than three mummified or stillborn
piglets, only 2 of them were sampled. On the con-
trary, at second farrowing cycle, foetal heart samples
from all the litters (n = 11, 7.33%) presenting high
number of mummified or stillborn piglets were taken
and evaluated. No microscopic lesions associated to
PCV2 infection or PCV2 antigen were observed in
myocardium of mummified or stillborn piglets from
all the tested litters.
Table 4 Reproductive parameters (mean ± SD) in PCV2 vaccinated (V) and non-vaccinated (NV) sows during both cycles
First gestational cycle Second gestational cycle
V (n = 94) NV (n = 97) V (n = 75) NV (n = 75)
Interval between expected and real farrowing date (days) 0.45 ± 2.07a 0.73 ± 1.36a 0.72 ± 1.57a 1.00 ± 1.33a
Live-born*/litter 14.34 ± 3.24a 13.61 ± 3.12a 15.42 ± 3.43a 14.16 ± 3.45b
Crushed/litter 0.53 ± 0.84a 0.43 ± 0.66a 0.95 ± 1.16a 0.73 ± 1.13a
Mummified/litter 0.35 ± 0.62a 0.44 ± 0.87a 0.38 ± 0.70a 0.47 ± 0.74a
Stillborn/litter 1.45 ± 1.72a 0.88 ± 1.36b 0.88 ± 1.05a 1.24 ± 1.35a
Weaned/litter 12.35 ± 2.89a 12.06 ± 2.71a 12.82 ± 2.75a 12.01 ± 3.31a
Vitality index (%)**-U
○ 1 (positive score) 91.91a 79.87b 97.14a 89.35a
Vitality index (%)**-NCC
○ ≥ 1 (positive score) 23.40a 10.69b 22.86a 10.19b
Weaning to fertile mating interval (days) 4.51 ± 2.53a 4.49 ± 2.67a NA NA
Abortion (%) 0a 1.0a 1.3a 0a
Different letters in superscript mean statistically significant differences (p < 0.05) among experimental groups within each reproductive cycle
NA: not available
*including crushed piglets at birth
**This index was calculated only from piglets of three or less hours of life
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Quantification of PCV2 DNA in sow serum samples
All vaccinated sows were qPCR negative (48 out of 48)
throughout the study, whilst 2 out of 48 (4.17%) non-
vaccinated sows were qPCR positive (mean viral load: 4.
15 log10 PCV2 copies/mL) at farrowing sampling of the
first reproductive cycle. No statistically significant dif-
ferences between treatment groups were observed.
Anti-PCV2 IgG antibody levels in sow serum samples
The course of antibodies against PCV2 for sows of the
two treatment groups is shown in Fig. 2. From 6 weeks
before farrowing to sampling at delivering of first gesta-
tional cycle, vaccinated group showed an increase of ELISA
S/P values, resulting in significantly higher (p < 0.05) anti-
body levels compared to the ones from the non-vaccinated
group at farrowing and weaning. In the second gestational
cycle, ELISA S/P values from vaccinated sows increased
again, reaching the maximum difference with the antibody
levels from the non-vaccinated counterparts.
Discussion
The objective of the present study was to evaluate the
potential effect of sow PCV2 vaccination in a PCV2 sub-
clinically infected breeding herd (PCV2 circulation but
absence of overt reproductive problems). The supporting
evidence of a subclinical infection was the presence of
seropositive gilts and sows before starting the trial to-
gether with the low percentage of viremic animals (less
than 5%) detected within the studied sow population.
This low prevalence would resemble the situation of
other PCV2-SI farms [31–33]. In parallel, in order to
have additional information about the PCV2 infection
status at the time when the study was carried out, blood
samples from 12 gilts at acclimatization were taken and
tested by qPCR. Indeed, PCV2 DNA was detected in 2
out of those 12 gilts (16.7%, data not shown), corrobor-
ating the PCV2-SI in the studied scenario.
Three criteria have to be fulfilled to diagnose a clinical
case of PCV2-RD during late gestation [6]: 1) presence
of clinical signs associated to late reproductive disorders
(abortions, increased number of mummified, stillborn
piglets at birth, etc.), 2) microscopic lesions in foetal
heart or lymphoid tissues, and 3) detection of PCV2
antigen or DNA in those foetal tissues. In addition,
return-to-oestrus problems have also been associated to
PCV2-RD at early gestation [34]. The negative results of
histopathology and IHC in all tested foetuses from litters
with high number of mummies and stillbirths indicated
that these findings were not apparently related to PCV2.
Therefore, as expected, the present farm was not suffering
from PCV2-RD (late reproductive failures or return-to-
oestrus), since the average of all reproductive parameters
were within normal ranges according to the Spanish na-
tional records.
In the present farm conditions, the PCV2 vaccination
strategy applied (primo-immunization at 6 and 3 weeks
pre-partum and a booster at 2 weeks before the subse-
quent farrowing) led to a significantly higher antibody
response throughout the study period with regard to
their non-vaccinated counterparts. This fact tallies with
other studies where sow vaccination before mating or far-
rowing elicited a high antibody response [31], including
neutralizing antibodies [35], in serum. In fact, the increase
of antibody levels measured by the used ELISA kit is
Fig. 2 PCV2 ELISA S/P results (mean ± SD) in serum samples taken from the sows included in the study during the first (6 weeks pre-farrowing,
farrowing, weaning) and second (farrowing) reproductive cycle. Different letters in superscript mean statistically significant differences (p < 0.05)
among experimental groups at each sampling point
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apparently correlated with PCV2 neutralizing antibody
values [36], although these were not specifically mea-
sured in this study. Besides, the booster vaccination at
the second cycle resulted in higher antibody levels than
the ones observed after first cycle vaccination, suggest-
ing a potential greater protection for both sows and
piglets. At reproductive level, sows immunized with the
PCV2 vaccine showed a significantly (p < 0.05) higher
number of live-born piglets and tend (p < 0.1) to have
higher number of weaned piglets per litter at the sec-
ond gestational cycle. In this study, sow vaccination at
first cycle was applied at a relatively late time during
pregnancy when the litter size is already established;
therefore, the potential impact of PCV2 vaccination on
litter size was only expected after second cycle vaccin-
ation. This effect on reproductive parameters is in line
with those observed by Pejsak et al. [28], but in dis-
agreement with the ones reported by Kurmann et al.
[23]. The first trial [28] was conducted in a farm with
important reproductive problems (most likely related
to PCV2-RD) and sporadic PCV2-SD cases. In that
study, the application of a 3-year PCV2 vaccination in
boars, gilts (at acclimatization) and sows (before far-
rowing) resulted in the improvement of all measured
reproductive parameters (insemination rate, number of
live-born and weaned piglets per litter and birth
weight). These positive effects were more evident after
several months of vaccine application, resembling the
findings of the present study. On the contrary, in the
other study [23], the application of PCV2 vaccine at 4
and 2 weeks before AI and 4 weeks pre-partum during
14 months in two farms with a history of recurrent
PCV2-SD in growing pigs but with no apparent repro-
ductive problems in sows did not culminate in better
reproductive parameters. Therefore, to the authors’
knowledge, the current study represents the first
approach in the peer-reviewed literature to show the
potential benefits of PCV2 sow vaccination on repro-
ductive parameters in a subclinically infected sow herd.
It must be kept in mind, however, that reproductive
performance may be influenced by other factors at farm
level [37]; in consequence, although the number of
studied sows is relatively high, the present study should
be considered of exploratory nature and a higher num-
ber of sows and production cycles would be needed to
validate obtained results.
Curiously enough, at the first farrowing post-vaccination,
the number of stillborns per litter was significantly higher
in the vaccinated group. The cause of this result is un-
known, as there was no evidence of any factor that could
adversely affect this parameter. Nevertheless, at the second
gestational cycle this situation was reversed, since vacci-
nated and non-vaccinated groups significantly reduced and
increased the number of stillborn piglets, respectively.
Generally, 10 to 15% of piglets are born dead in pig farms
[38]; therefore, the stillborn rate reported in the present
study falls within regular values in both reproductive cy-
cles. This parameter might be related to hypoxia during
farrowing since the number of stillbirths increases in cases
of high litter size, prolonged farrowing time and high birth
weight [39, 40]. Besides, stillbirth can be associated with
other factors such as environmental temperature, sow
parity, farrowing induction, infectious diseases, myco-
toxins and uterine capacity [41].
Moreover, piglets from vaccinated sows had higher
vitality (in the first three hours of life) than the animals
issued from non-vaccinated ones in both reproductive
cycles. This finding was subjectively reported in a farm
with major reproductive problems, most probably re-
lated to PCV2, using the same vaccine than the present
study [28]. Besides, since VI was higher in piglets coming
from vaccinated sows, one would expect to have less
crushed piglets in that group. However, vaccinated sows
showed higher (but non-significantly) number of crushed
piglets. Most probably, this was a fortuitous event and not
associated to piglet vitality, since crushing is related to
other factors such as sow behaviour (depends of the sow
genetics), design of farrowing crates and management
practices [42].
Conclusions
After two reproductive cycles, sows vaccinated against
PCV2 experienced significantly higher antibody levels,
prolificacy and vitality of their offspring. However, as re-
productive performance may be influenced by multiple
factors, the present study represents a further investi-
gation of the PCV2 sow vaccination effects on repro-
ductive parameters under a PCV2 subclinical infection
scenario.
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